Citations (12)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Sunita , Yogendra Singh, Gillian Beamer, Xingmin Sun & Pratyoosh Shukla. (2022) Recent developments in systems biology and genetic engineering toward design of vaccines for TB. Critical Reviews in Biotechnology 42:4, pages 532-547.
Read now
Read now
Austin Hoggarth, Andrew Weaver, Qinqin Pu, Ting Huang, Jacob Schettler, Feng Chen, Xiefang Yuan & Min Wu. (2019) Mechanistic research holds promise for bacterial vaccines and phage therapies for Pseudomonas aeruginosa. Drug Design, Development and Therapy 13, pages 909-924.
Read now
Read now
Articles from other publishers (10)
Jesús Bernardino Velázquez-Fernández, Gustavo Henrique Martins Ferreira-Souza, Jacobo Rodríguez-Campos, Michel de Jesús Aceves-Sánchez, Jorge Bravo-Madrigal, Alba Adriana Vallejo-Cardona & Mario Alberto Flores-Valdez. (2020) Proteomic characterization of a second-generation version of the BCGΔBCG1419c vaccine candidate by means of electrospray-ionization quadrupole time-of-flight mass spectrometry. Pathogens and Disease 79:1.
Crossref
Crossref
Aïcha Bah, Merlin Sanicas, Jérôme Nigou, Christophe Guilhot, Catherine Astarie-Dequeker & Isabelle Vergne. (2020) The Lipid Virulence Factors of Mycobacterium tuberculosis Exert Multilayered Control over Autophagy-Related Pathways in Infected Human Macrophages. Cells 9:3, pages 666.
Crossref
Crossref
Cristian Alfredo Segura-Cerda, Michel de Jesús Aceves-Sánchez, Vadim Pérez-Koldenkova & Mario Alberto Flores-Valdez. (2019) Macrophage infection with combinations of BCG mutants reduces induction of TNF-α, IL-6, IL-1β and increases IL-4. Tuberculosis 115, pages 42-48.
Crossref
Crossref
Steven C. Kennedy, Alison J. Johnson, Sushma Bharrhan, Cecilia S. Lindestam Arlehamn, Jiayong Xu, Scott J. Garforth, John Chan, William R. JacobsJr.Jr., Alessandro Sette, Steven C. Almo & Steven A. Porcelli. (2018)
Identification of Mycobacterial Ribosomal Proteins as Targets for CD4
+
T Cells That Enhance Protective Immunity in Tuberculosis
. Infection and Immunity 86:9.
Crossref
Crossref
Catherine Vilchèze, Jacqueline Copeland, Tracy L. Keiser, Torin Weisbrod, Jacqueline Washington, Paras Jain, Adel Malek, Brian Weinrick & William R. JacobsJr.Jr.. (2018) Rational Design of Biosafety Level 2-Approved, Multidrug-Resistant Strains of Mycobacterium tuberculosis through Nutrient Auxotrophy. mBio 9:3.
Crossref
Crossref
Stefan Köster, Thais Klevorn, Kadamba Papavinasasundaram, Christopher M. Sassetti, Cynthia Portal-Celhay & Jennifer A. Philips. (2018) Consequence of enhanced LC3-trafficking for a live, attenuated M. tuberculosis vaccine. Vaccine 36:7, pages 939-944.
Crossref
Crossref
Shin-ichiro Fujii & Kanako Shimizu. (2017) Exploiting Antitumor Immunotherapeutic Novel Strategies by Deciphering the Cross Talk between Invariant NKT Cells and Dendritic Cells. Frontiers in Immunology 8.
Crossref
Crossref
Alison J. Johnson, Steven C. Kennedy, Cecilia S. Lindestam Arlehamn, Michael F. Goldberg, Neeraj K. Saini, Jiayong Xu, Sinu Paul, Subray S. Hegde, John S. Blanchard, John Chan, William R. JacobsJr.Jr., Alessandro Sette & Steven A. Porcelli. (2017)
Identification of Mycobacterial RplJ/L10 and RpsA/S1 Proteins as Novel Targets for CD4
+
T Cells
. Infection and Immunity 85:4.
Crossref
Crossref
César Pedroza-Roldán, Carolina Guapillo, Jorge Barrios-Payán, Dulce Mata-Espinosa, Michel de Jesús Aceves-Sánchez, Brenda Marquina-Castillo, Rogelio Hernández-Pando & Mario Alberto Flores-Valdez. (2016) The BCGΔBCG1419c strain, which produces more pellicle in vitro, improves control of chronic tuberculosis in vivo. Vaccine 34:40, pages 4763-4770.
Crossref
Crossref
Leandro J Carreño, Noemí A Saavedra-Ávila & Steven A Porcelli. (2016) Synthetic glycolipid activators of natural killer T cells as immunotherapeutic agents. Clinical & Translational Immunology 5:4, pages e69.
Crossref
Crossref